 |
CTSI Pilot Grant Award Program Catalyzes Cross-Institutional
and Multidisciplinary Collaboration
In 2022, we are pleased to report that 46 investigators from across BMC and both BU Medical and Charles River campuses, applied to the Integrated Pilot Award Program sponsored by the BU Clinical and Translational Science Institute. Twenty pilot projects were funded that totaled $768,305 to investigators across BMC, BUSM Department of Medicine, College of Arts and Sciences, College of Engineering, School of Public Health, School of Social Work, School
of Medicine, and Goldman School of Dental Medicine. Read More
|
|
|
|
|
Program for Early Research Career Development
Application Deadline: Sept.16, 2022
This Program will provide a roadmap and targeted guidance for senior post-doctoral fellows and early career faculty (both MD and PhD) committed to launching an independent research career. Learn More
|
BU CTSI NIH Diversity Supplement
Application Deadline: Sep.16, 2022
The goal of these supplements is to build a diverse clinical and translational research workforce that is prepared to improve the quality, safety, efficiency, and speed of clinical and translational science research nationally.
|
Integrated Pilot Grant Award Program
Application Due Date: Sep. 30, 2022
The overarching goal of the BU CTSI Pilot Grant Program is to help investigators explore and solve major challenges in translational science, especially those that address the special health problems of our urban communities. Learn More.
|
BU CTSI NIH Diversity Supplement Matching Initiative
The BU CTSI is committed to increasing our institution’s biomedical researcher diversity by connecting eligible early career scientists with Principal Investigators who have grants eligible for Diversity Supplements. Learn More
|
The BU CTSI Voucher Program
Applications are Accepted on a Rolling Basis.
This Program supports the short-term needs of investigators that are not otherwise covered by grants. Vouchers are intended to enable preliminary work, generate data for new or ongoing projects, and/or secure fee-based core services for consultation services. Learn More
|
Save the Date!
October 12, 2022 (Via Zoom)
In Memory of
David C. Seldin MD, PhD
(1957-2015)
Keynote Speaker:
Susan Cheng, MD, MMSc, MPH
|
|
|
|
|
HEAL Initiative: Opioid Exposure and Effects on Placenta Function, Brain Development, & Neurodevelopmental Outcomes (R21 Basic Experimental Studies with Humans Required)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
|
Notice of Special Interest (NOSI): Small Research Grants for Innovations in Healthy Longevity Research
National Institute on Aging (NIA)
|
Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
|
|
|
Notice of Special Interest (NOSI): Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)
Office of Research on Women's Health (ORWH)
|
Notice of Special Interest (NOSI): Development and Preliminary Testing of Health-related Behavioral Interventions
Office of Behavioral and Social Sciences Research (OBSSR)
|
Agency for Healthcare Research and Quality (AHRQ)-sponsored National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
Agency for Healthcare Research and Quality (AHRQ)
|
|
|
|
Notice of Special Interest: Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents (Admin Supp - Clinical Trial Not Allowed)
Office of Dietary Supplements (ODS)
|
Notice of Special Interest (NOSI): Basic and Translational Research on Circadian Regulation of Heart, Lung, Blood, and Sleep Disorders (R01)
National Heart, Lung, and Blood Institute (NHLBI)
|
Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT) Centers (U54 Clinical Trial Not Allowed)
National Cancer Institute (NCI)
|
|
|
|
|
Risk of BA.5 Infection Among Persons Exposed to Previous SARS-CoV-2 Variants
Overall, we found that breakthrough infections with the BA.5 subvariant were less likely among persons with a previous SARS-CoV-2 infection history in a highly vaccinated population, especially for previous BA.1 or BA.2 infection, than among uninfected persons. Read More
|
|
|
|
|
U.S. Clinical Trial Evaluating Antiviral
for Monkeypox Begins
In rare cases, monkeypox virus can cause serious complications, including dehydration, bacterial infections, pneumonia, brain inflammation, sepsis, eye infections and
|
|
|
|
|
Building Your Team Science Toolbox
Sep. 21, 2022, 1 pm
In this highly participatory installment of the ACTS Professional Development Roundtables, we will address a series of questions related to team science. Learn More
|
|
|
|
|
Genomic Medicine in Clinical Practice
Application Due Date: Sep. 26, 2022
CTSA member: $712
This course aims to equip healthcare professionals, researchers, and medical students who are interested in learning more about the current and future applications of genomic medicine. Learn More
|
|
|
|
|
NIH HEAL Sickle Cell Disease and Pain Management Technical Assistance Webinar
Oct. 4, 2022, 2 pm
Join the NIH HEAL Initiative®, to learn about two funding opportunity announcements (FOAs) for studies on sickle cell disease (SCD) pain management. Learn More
|
|
|
|
|
The Funding Acknowledgement |
|
|
|
|
The Funding Acknowledgement guides recipients of BU CTSI services, resources, or funding for projects or research through the grant citation process. All recipients are required to cite our grant number in associated presentations and journal publications.
|
|
|
|
|
|
|
|
|
